The pharmaceutical company said late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in ...

My methodology for selecting pharmaceutical companies with the best risk/reward ratio Before I move on to discuss the global oncology drugs ... factors driving up its share price.

Amgen AMGN announced encouraging new data from its interim analysis of the global late-stage study evaluating Imdelltra ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...

Officially completing its acquisition of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT), Sun Pharmaceutical Industries Ltd. has ...

Mumbai: Sun Pharmaceutical Industries Limited has announced the successful completion of its acquisition of Checkpoint ...

Share on Facebook ... to improve understanding of the risk of radiation therapy-associated cardiac arrhythmias. (JACC: CardioOncology) The American Cancer Society and Color Health announced ...

Big Pharma will hunt for more acquisitions in 2025 as industry giants face patent expiration for some of their best-selling drugs, according to a top M&A banker. Merck's cancer drug Keytruda ...

Isabel joined Newsweek in July 2024, after covering the pharmaceutical ... share unique social, economic, political, and climate environments, which affect their exposure to cancer risk factors ...

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients ... please refer to the Risk Factors (“Facteurs de Risque") section of ...